Agnes is an expert in the development of replacement therapies for rare disorders. While working at BioMarin, a major orphan drug developer, Agnes saw an opportunity to work on unaddressed diseases to make a difference for the lives of patients and their families and left to found Glycomine. Glycomine represents her passion for glycobiology combined with her expertise in nanotechnology and orphan drug. She believes that the innovative combination of nanotechnology and medicine (nanomedicine) will allow for creation of treatment options for many rare diseases.
Agnes previously worked as a Scientist within the protein analytical development division of Intrexon and small molecule manufacturing at Pfizer. Agnes obtained a B.S. in Chemistry from University of Saint Joseph and a Ph.D. in Chemistry with a focus on Proteomics and Nanomedicine at Northeastern University.